Cargando…

Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers

Background: Ticagrelor belongs to a new class of P2Y(12) receptor inhibitor that has been widely used for antiplatelet therapy. This study aimed to explore the effect of single nucleotide polymorphisms (SNPs) in metabolic enzymes, transporters, and other relevant variants on the pharmacokinetics (PK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nie, Shanshan, Chen, Kaifeng, Guo, Chengxian, Pei, Qi, Zou, Chan, Yao, Liangyuan, Yuan, Hongbo, Zhao, Xia, Xie, Ran, He, Xu, Huang, Jie, Yang, Guoping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915292/ https://www.ncbi.nlm.nih.gov/pubmed/35280252 http://dx.doi.org/10.3389/fphar.2021.797278

Ejemplares similares

Effect of CYP3A4(∗)1G and CYP3A5(∗)3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects
por: Liu, Shuaibing, et al.
Publicado: (2017)

Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2013)

Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients
por: Matthaei, Johannes, et al.
Publicado: (2021)

Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2013)

Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers
por: Zou, Chan, et al.
Publicado: (2019)

Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015)

Population pharmacokinetic analysis of transdermal granisetron in healthy Chinese and Caucasian volunteers
por: Li, Jiayu, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacogenetic Factors Contributing to Platelet Function Recovery After Single Dose of Ticagrelor in Healthy Subjects
por: Zhu, Qian, et al.
Publicado: (2019)

Pharmacokinetic Modeling of Morphine’s Effect on Plasma Concentrations of Ticagrelor and Its Metabolite in Healthy Volunteers
por: Buszko, Katarzyna, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials
por: Chaoyang, Chen, et al.
Publicado: (2022)

Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2014)

Serum Predose Metabolic Profiling for Prediction of Rosuvastatin Pharmacokinetic Parameters in Healthy Volunteers
por: Silveira, Anne Michelli Reis, et al.
Publicado: (2021)

Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection
por: Guan, Xiao-duo, et al.
Publicado: (2021)

Single- and Multiple-Dose Trials to Determine the Pharmacokinetics, Safety, Tolerability, and Sex Effect of Oral Ginsenoside Compound K in Healthy Chinese Volunteers
por: Chen, Lulu, et al.
Publicado: (2018)

CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers
por: Gawrońska-Szklarz, Barbara, et al.
Publicado: (2012)

Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers
por: Jung, Eben, et al.
Publicado: (2018)

Evaluation of the relationship between polymorphisms in CYP2C19 and the single‐dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study
por: Zhou, Shuang, et al.
Publicado: (2022)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Single Dose Study Assessing the Pharmacokinetic and Metabolic Profile of Alverine Citrate in Healthy Volunteers
por: Rizea-Savu, Simona, et al.
Publicado: (2021)

Joint population pharmacokinetic modeling of venlafaxine and O-desmethyl venlafaxine in healthy volunteers and patients to evaluate the impact of morbidity and concomitant medication
por: Wang, Zhanzhang, et al.
Publicado: (2022)

Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2021)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
por: Monteith, David, et al.
Publicado: (2017)

Corrigendum: Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta(®) in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2022)

Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers
por: Aquilante, Christina L, et al.
Publicado: (2008)

The Effects of Warfarin on the Pharmacokinetics of Senkyunolide I in a Rat Model of Biliary Drainage After Administration of Chuanxiong
por: Li, Haigang, et al.
Publicado: (2018)

Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A
por: Rafehi, Muhammad, et al.
Publicado: (2019)

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
por: Calleja, Sofía, et al.
Publicado: (2023)

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
por: Grzegorzewski, Jan, et al.
Publicado: (2022)

A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers
por: Liu, Ruijuan, et al.
Publicado: (2019)

Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study
por: Azzahhafi, Jaouad, et al.
Publicado: (2022)

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers
por: Li, Xiaojiao, et al.
Publicado: (2018)

Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response
por: Zhang, J. E., et al.
Publicado: (2017)

Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2023)

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
por: Ma, Tingting, et al.
Publicado: (2022)

Effects of gut microbiota on the pharmacokinetics of protopanaxadiol ginsenosides Rd, Rg3, F2, and compound K in healthy volunteers treated orally with red ginseng
por: Kim, Jeon-Kyung, et al.
Publicado: (2020)

Pharmacokinetic interaction of voriconazole and clarithromycin in Pakistani healthy male volunteers: a single dose, randomized, crossover, open-label study
por: Mushtaq, Mehwish, et al.
Publicado: (2023)

The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers
por: Schneider, F., et al.
Publicado: (2021)

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects
por: Vourvahis, Manoli, et al.
Publicado: (2018)

Pharmacokinetics, Urinary Excretion, and Pharmaco-Metabolomic Study of Tebipenem Pivoxil Granules After Single Escalating Oral Dose in Healthy Chinese Volunteers
por: Li, Zeyun, et al.
Publicado: (2021)

Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization
por: Gu, Meng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_knu00ljvir1bn5d7b0h7nkp2e0